Provided by Tiger Trade Technology Pte. Ltd.

Fidelity MSCI Health Care Index ETF

80.46
-0.5100-0.63%
Volume:1.73M
Turnover:139.56M
Market Cap:3.38B
PE:- -
High:81.12
Open:80.90
Low:80.41
Close:80.97
52wk High:85.46
52wk Low:64.30
Shares:42.00M
Float Shares:42.00M
Volume Ratio:8.97
T/O Rate:4.13%
Dividend:1.02
Dividend Rate:1.27%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

TIPRANKS
·
2 hours ago

MS Cuts Novo Nordisk on Growth Prospects, Patent Expiry Risks

Reuters
·
3 hours ago

Growth Without AI: 8 Stock Picks

Dow Jones
·
5 hours ago

Nextbiomedical Targets Global Investors at 2026 KIS BioTech Day

TIPRANKS
·
8 hours ago

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
13 hours ago

GeoVax Updates Nasdaq Listing Amid Ongoing Clinical Progress

TIPRANKS
·
13 hours ago

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
14 hours ago

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
14 hours ago

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
16 hours ago

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
16 hours ago

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
18 hours ago

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Reuters
·
Yesterday

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Yesterday

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Yesterday

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Yesterday

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Yesterday

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Yesterday

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Yesterday

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Yesterday

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Yesterday